Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Detail)

v3.4.0.3
Fair Value Measurements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended
Oct. 31, 2015
Mar. 17, 2014
Mar. 31, 2016
Mar. 31, 2015
Feb. 29, 2016
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Equity Method Investments   $ 250,000 $ 250,000     $ 250,000
Equity Method Investment, Ownership Percentage   35.00%        
Share Price     $ 9.61      
Fair Value Assumptions, Weighted Average Volatility Rate     25.60%      
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total     $ 900,000      
Investment Owned, at Fair Value     $ 1,300,000      
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants     25.00%      
Fair Value Adjustment of Warrants     $ 89,000 $ 0    
Business Acquisition, Percentage of Voting Interests Acquired     10.25%      
CB Pharma Acquisitions Corp [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Working Capital     $ 500,000      
Working Capital Committed     $ 300,000      
Common Stock Subject to Mandatory Redemption [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Net Assets         $ 42,500,000  
Non Redeemable warrants [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Share Price     $ 0.10      
Redeemable warrants [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Share Price     $ 0.10      
NSE Note [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Warrant Expiration Period     10 years      
Fair Value Adjustment of Warrants $ 3,000,000          
Binomial Lattice Model [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value Assumptions, Exercise Price     $ 11.50      
Fair Value Assumptions, Risk Free Interest Rate     1.21%      
Fair Value Assumptions, Expected Volatility Rate     25.60%      
Binomial Lattice Model [Member] | Warrant [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Share Price     $ 0.98      
Ghaidarov Model [Member] | Warrant [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Share Price     0.94      
Private Units [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Share Price     1.00      
Share Price     9.82      
Insider Shares [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Share Price     $ 0.97      
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Shares Received Under Purchase Agreement   $ 13,409,962        
Percentage Of Shares Received Under Purchase Agreement   83.00%        
Preferred Units, Issued   16,091,954